top of page

Cosmos

Papers & Publications

Our peer-reviewed publications, scientific papers, and conference presentations showcase the research foundation behind Sur180 Therapeutics’ novel approach to endometriosis. This body of work reflects our commitment to scientific rigor, data-driven innovation, and the translation of validated research into patient-focused therapeutic solutions.

Beyond depression and anxiety; a systematic review about the role of corticotropin- releasing hormone antagonists in diseases of the pelvic and abdominal organs.

Efficacy of an environmental enrichment intervention for endometriosis: a pilot study.

Feasibility and acceptability of an adapted environmental enrichment intervention for endometriosis: A pilot study.

Metabolomics in endometriosis: challenges and perspectives for future studies.

The Link Between Stress and Endometriosis: from Animal Models to the Clinical Scenario

Short treatment with antalarmin alters adrenal gland receptors in the rat model of endometriosis

Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis

Environmental Manipulations as an Effective Alternative Treatment to Reduce Endometriosis Progression

Impact of Psychological Stress on Pain Perception in an Animal Model of Endometriosis.

Endometriosis Is Associated With a Shift in MU Opioid and NMDA Receptor Expression in the Brain Periaqueductal Gray

Antagonizing the corticotropin-releasing hormone receptor 1 with an orally bioavailable drug reduces endometriosis pain and associated adhesions

Patents

US10729693B2
United States

Compositions and methods for the treatment of endometriosis.

Sur180 Therapeutics has exclusive licensing rights to this patent.

US Application Number 63/688,026

New patent filing

Sur180 Therapeutics jointly owns this patent application

bottom of page